Search Results 7881-7890 of 33459 for oral

  1. Mayo Clinic Q and A: Osteoporosis and supplements for bone health

    Osteoporosis is a condition that causes the bones to thin and lose their strength. When bones become weaker, sudden fractures can occur, even with minimal ...

  2. Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies - Mayo Clinic

    ... oral contraceptives, some intrauterine devices, sexual abstinence, or vasectomized partner. Exclusion Criteria: Had eculizumab therapy within three months ...

  3. Meralgia paresthetica - Symptoms and causes - Mayo Clinic

    Gabapentin oral. Facts & Comparisons eAnswers. https://fco.factsandcomparisons.com. Accessed Dec. 11, 2023. Tricyclic antidepressants. Facts & Comparisons ...

  4. Hematology - Clinical trials

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...

  5. Nasopharyngeal carcinoma - Doctors and departments - Mayo Clinic

    ... Oral and throat cancer, Salivary gland cancer, Mouth cancer, Thyroid cancer, Head and neck cancer, Melanoma, Tonsil cancer, Skin cancer, Squamous cell ...

  6. Evaluate The Safety, Tolerability, Pharmacokinetics And Efficacy Of BL-M05D1 In Subjects With Solid Tumors - Mayo Clinic

    Subjects on stable oral antimicrobials with no clinical or laboratory evidence of active infection are eligible 21. Subjects who are pregnant, breastfeeding ...

  7. PR3-AAV Resilient Remission or PRRR - Mayo Clinic

    ... (oral, injectable, implant or ring); 3) barrier contraceptives (condom or diaphragm) with spermicide; or 4) abstinence. Exclusion Criteria: - Diagnosis with ...

  8. A Study to Test Sacituzumab Govitecan Therapy in Patients with HER2-Negative Breast Cancer and Brain Metastases - Mayo Clinic

    Participants who are able to switch to low molecular weight heparin (LMWH) or direct oral anticoagulants (DOACs) prior to date of registration (and plan to ...

  9. Safety and Efficacy Study of Filgotinib, GS-9876 and Tirabrutinib in Adults With Active Sjogren's Syndrome - Mayo Clinic

    Stable dose (defined as no change in prescription for at least 4 weeks prior to Day 1) of NSAIDs, HCQ, MTX and/or oral corticosteroids is permitted during ...

  10. Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer - Mayo Clinic

    Able to swallow oral formulation of the study agent; Hemoglobin >= 9 g/dL; Platelet count >= 75,000/mm^3; Creatinine =< 1.5 x upper limits of normal (ULN) ...